MX2011008752A - Variantes de union a anti-albumina de suero mejoradas. - Google Patents

Variantes de union a anti-albumina de suero mejoradas.

Info

Publication number
MX2011008752A
MX2011008752A MX2011008752A MX2011008752A MX2011008752A MX 2011008752 A MX2011008752 A MX 2011008752A MX 2011008752 A MX2011008752 A MX 2011008752A MX 2011008752 A MX2011008752 A MX 2011008752A MX 2011008752 A MX2011008752 A MX 2011008752A
Authority
MX
Mexico
Prior art keywords
serum albumin
albumin binding
improved anti
binding variants
variants
Prior art date
Application number
MX2011008752A
Other languages
English (en)
Inventor
Carolyn Enever
Angelis Elena De
Haiqun Liu
Oliver Schon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2011008752A publication Critical patent/MX2011008752A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a variantes mejoradas del dominio variable sencillo de inmunoglobulina anti-albúmina de suero DOM7h-14, así como a ligandos y conjugados de fármacos que comprenden dichas variantes, composiciones, ácido nucleicos, vectores y huéspedes.
MX2011008752A 2009-02-19 2010-02-17 Variantes de union a anti-albumina de suero mejoradas. MX2011008752A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16399009P 2009-03-27 2009-03-27
PCT/EP2010/052007 WO2010094722A2 (en) 2009-02-19 2010-02-17 Improved anti-serum albumin binding variants

Publications (1)

Publication Number Publication Date
MX2011008752A true MX2011008752A (es) 2011-09-06

Family

ID=42306619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008752A MX2011008752A (es) 2009-02-19 2010-02-17 Variantes de union a anti-albumina de suero mejoradas.

Country Status (23)

Country Link
US (2) US9175071B2 (es)
EP (1) EP2398825B1 (es)
JP (1) JP5766616B2 (es)
KR (1) KR101820968B1 (es)
CN (2) CN102405232B (es)
AR (1) AR075506A1 (es)
AU (2) AU2010215481C1 (es)
BR (1) BRPI1008705B1 (es)
CA (1) CA2753130C (es)
CL (1) CL2011002023A1 (es)
CO (1) CO6450689A2 (es)
DO (1) DOP2011000269A (es)
EA (1) EA027866B1 (es)
ES (1) ES2654929T3 (es)
IL (1) IL214481A0 (es)
MA (1) MA33052B1 (es)
MX (1) MX2011008752A (es)
PE (1) PE20120170A1 (es)
SG (1) SG173488A1 (es)
TW (1) TW201042041A (es)
UY (1) UY32452A (es)
WO (1) WO2010094722A2 (es)
ZA (1) ZA201105658B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0922772B1 (pt) * 2008-12-05 2021-09-08 Glaxo Group Limited Domínio variável único de imunoglobulina e polipeptídeos isolados
CA3079184A1 (en) 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-serum albumin binding variants
CN104127880A (zh) * 2009-03-27 2014-11-05 葛兰素集团有限公司 药用融合体和缀合物
US20120276098A1 (en) * 2009-09-30 2012-11-01 Bruce Hamilton Drug fusions and conjugates with extended half life
CN103003303A (zh) 2010-05-20 2013-03-27 葛兰素集团有限公司 改进的抗-血清白蛋白结合变体
WO2012020143A1 (en) * 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants
EA201390450A1 (ru) * 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
WO2012072731A2 (en) 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
US11028166B2 (en) 2017-02-16 2021-06-08 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
EP3634997A1 (en) * 2017-06-05 2020-04-15 Numab Therapeutics AG Novel anti-hsa antibodies
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3807311A4 (en) * 2018-04-24 2022-01-26 National Research Council of Canada SERUM ALBUMIN BINDING ANTIBODIES FOR ADJUSTABLE HALF-LIFE EXTENSION OF BIOLOGICALS
KR102204315B1 (ko) * 2018-11-16 2021-01-18 한국세라믹기술원 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19713272A1 (de) 1997-03-29 1998-10-08 Junghans Uhren Gmbh Zeitzonen-Uhr
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
WO2006059110A2 (en) 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
US20090214534A1 (en) 2004-12-02 2009-08-27 Steve Holmes Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
KR20110092328A (ko) 2008-11-26 2011-08-17 글락소 그룹 리미티드 Ｉｌ-13에 결합하는 리간드

Also Published As

Publication number Publication date
UY32452A (es) 2010-09-30
WO2010094722A2 (en) 2010-08-26
AU2014202764A1 (en) 2014-06-12
US9175071B2 (en) 2015-11-03
KR20110127224A (ko) 2011-11-24
DOP2011000269A (es) 2011-12-31
JP2012517819A (ja) 2012-08-09
SG173488A1 (en) 2011-09-29
CN105061593B (zh) 2018-08-03
KR101820968B1 (ko) 2018-01-23
BRPI1008705B1 (pt) 2021-05-25
WO2010094722A3 (en) 2011-01-13
US20160075774A1 (en) 2016-03-17
JP5766616B2 (ja) 2015-08-19
MA33052B1 (fr) 2012-02-01
AU2010215481A1 (en) 2011-08-25
EA027866B1 (ru) 2017-09-29
US20110300158A1 (en) 2011-12-08
CN105061593A (zh) 2015-11-18
EP2398825A2 (en) 2011-12-28
CO6450689A2 (es) 2012-05-31
CA2753130A1 (en) 2010-08-26
AU2010215481C1 (en) 2015-06-04
CN102405232B (zh) 2015-08-19
CN102405232A (zh) 2012-04-04
AU2014202764B2 (en) 2016-07-07
ZA201105658B (en) 2012-05-25
PE20120170A1 (es) 2012-03-21
EP2398825B1 (en) 2017-10-25
BRPI1008705A2 (pt) 2016-03-08
IL214481A0 (en) 2011-09-27
AR075506A1 (es) 2011-04-06
US9751935B2 (en) 2017-09-05
ES2654929T3 (es) 2018-02-15
CL2011002023A1 (es) 2012-04-09
TW201042041A (en) 2010-12-01
EA201171067A1 (ru) 2012-02-28
CA2753130C (en) 2020-07-14
AU2010215481B2 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012000765A (es) Dominios variables sencillos de union de albumina anti-suero mejorados.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
AU2015370918A8 (en) Binding protein drug conjugates comprising anthracycline derivatives
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX2012003939A (es) Fusiones y conjugados de farmaco.
WO2011086143A3 (en) Liver targeting domain antibodies
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
CA2817002A1 (en) Base modified oligonucleotides
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
WO2011112566A3 (en) Basigin binding proteins
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
CA3036643C (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.
NZ626296A (en) Compositions and methods for antibodies targeting factor p

Legal Events

Date Code Title Description
FA Abandonment or withdrawal